{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 2 of 2 results
Status:
Possibly Marketed Outside US
Source:
M028
(2023)
Source URL:
First approved in 2023
Source:
M028
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
SOMA Anti-Cancergen by SOMA Biotechnology Co., Ltd
(2013)
Source URL:
First approved in 2013
Source:
SOMA Anti-Cancergen by SOMA Biotechnology Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE